RIPK1 and pancreatic neoplasm: For instance, RIPK1 (one of our 67 NRGs, also a common NRGs) is heavily expressed by TAMs in pancreatic cancer wherein RIPK1 facilitates TAMs-driven immunosuppression (19), and the pharmacological inhibitors of RIPK1 in pancreatic cancer patients (with or without combination with anti-PD1 immunotherapy) with the aim to ameliorate the immunosuppressive tumor milieu (20).